Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 7c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.54), $0.07 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $172.3 million versus the consensus estimate of $161.36 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Morgan Stanley Downgrades Peloton Interactive (PTON) to Underweight
• Citi upgrades C.H. Robinson to Buy with $185 target, Opens 90-Day upside catalyst watch